Bibliography

Found 48 results
Filters: Author is CHARTER Group  [Clear All Filters]
2012
Choi JYong, Hightower GK, Wong JK, Heaton R, Woods S, Grant I, Marcotte TD, Ellis RJ, Letendre SL, Collier AC, et al. Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
Keltner JR, Vaida F, Ellis RJ, Moeller-Bertram T, Fitzsimmons C, Duarte NA, Robinson-Papp J, Dworkin RH, Clifford DB, McArthur JC, et al. Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity. Psychosomatics. 2012 ;53(4):380-6.
Croteau D, Best BM, Letendre S, Rossi SS, Ellis RJ, Clifford DB, Collier AC, Gelman BB, McArthur JC, McCutchan JAllen, et al. Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS. 2012 ;26(7):890-3.
Holzinger ER, Hulgan T, Ellis RJ, Samuels DC, Ritchie MD, Haas DW, Kallianpur AR, Bloss CS, Clifford DB, Collier AC, et al. Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012 ;18(6):511-20.
McCutchan JA, Marquie-Beck JA, Fitzsimons CA, Letendre SL, Ellis RJ, Heaton RK, Wolfson T, Rosario D, Alexander TJ, Marra C, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012 ;78(7):485-92.
Croteau D, Letendre S, Best BM, Rossi SS, Ellis RJ, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur J, et al. Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 ;56(4):1985-9.
2011
Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011 ;25(14):1747-51.
Jernigan TL, Archibald SL, Fennema-Notestine C, Taylor MJ, Theilmann RJ, Julaton MD, Notestine RJ, Wolfson T, Letendre SL, Ellis RJ, et al. Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AC, Gelman BB, Mbeo G, J McCutchan A, et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 ;66(2):354-7.
Lin K, Taylor MJ, Heaton R, Franklin D, Jernigan T, Fennema-Notestine C, McCutchan A, J Atkinson H, Ellis RJ, McArthur J, et al. Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. J Clin Exp Neuropsychol. 2011 ;33(3):326-34.
Heaton RK, Franklin DR, Ellis RJ, J McCutchan A, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011 ;17(1):3-16.
Moore DJ, Letendre SL, Morris S, Umlauf A, Deutsch R, Smith DM, Little S, Rooney A, Franklin DR, Gouaux B, et al. Neurocognitive functioning in acute or early HIV infection. J Neurovirol. 2011 ;17(1):50-7.
Byrd DA, Fellows RP, Morgello S, Franklin D, Heaton RK, Deutsch R, J Atkinson H, Clifford DB, Collier AC, Marra CM, et al. Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr. 2011 ;58(2):154-62.
Cysique LA, Franklin D, Abramson I, Ellis RJ, Letendre S, Collier A, Clifford D, Gelman B, McArthur J, Morgello S, et al. Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol. 2011 ;33(5):505-22.

Pages